Results 31 to 40 of about 6,366 (244)

High-sensitivity troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer agents for breast cancer in patients with predominantly low and moderate risk of cardiotoxicity

Российский кардиологический журнал, 2022
Aim. To study the significance of monitoring high-sensitivity troponin I (hs-cTnI) for predicting anthracycline-induced left ventricular (LV) dysfunction in the treatment of breast cancer in patients with moderate and low risk of cardiotoxicity (CT ...
V. D. Levina, M. G. Poltavskaya, P. Sh. Chomakhidze, A. A. Meshcheryakov, L. V. Bolotina, T. I. Deshkina, D. S. Valiulina, A. N. Gerasimov, O. V. Andreeva, A. A. Shmeleva, Z.Z.A. Fashafsha, A. R. Levshina, V. P. Sedov   +12 more
doaj   +1 more source

Redefining the role of anthracyclines in early breast cancer treatment

Academia Oncology
Anthracyclines have long been a cornerstone of early breast cancer treatment, contributing to significant reductions in recurrence and improvements in survival.
Guilherme Nader-Marta, Martine Piccart
doaj   +1 more source

Novel Polyhedral Silsesquioxanes [POSS(OH)₃₂] as Anthracycline Nanocarriers—Potential Anticancer Prodrugs

Molecules, 2020
Anthracyclines belong to the anticancer drugs that are widely used in chemotherapy. However, due to their systemic toxicity they also exert dangerous side effects associated mainly with cardiovascular risks.
Kinga Piorecka, Jan Kurjata, Wlodzimierz A. Stanczyk   +2 more
doaj   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Naturally Occurring Anthracyclines

, 2008
The present article gives an overview of the natural occurring anthracyclines and anthracyclinones reported from microorganisms. A general description, discussion of their physicochemical properties, including NMR increments, and their structural ...
Fotso, Serge, Serge Fotso, Laatsch, Hartmut, Hartmut Laatsch   +3 more
core   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling

FEBS Open Bio, EarlyView.
Pharmacological inhibition of PERK in a DEN‐induced mouse model of liver cancer does not reduce tumor burden but alters cellular stress signaling. Despite blocking PERK activity, downstream stress responses, including CHOP expression, remain active, suggesting compensatory mechanisms within the unfolded protein response that may influence tumor ...
Ada Lerma‐Clavero, Maria Kopsida, Nathalie Arendt, Hans Lennernäs, Markus Sjöblom, Femke Heindryckx   +5 more
wiley   +1 more source

Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines

Cardio-Oncology
Venetoclax is a promising drug for patients with acute myeloid leukemia (AML) ineligible for anthracycline-based treatments. In rats, venetoclax is reported to cause myocardial injury.
Takeshi Onoue, Andrew H. Matthews, Azin Vakilpour, Yu Kang, Bénédicte Lefebvre, Amanda M. Smith, Shannon R. McCurdy, Michael G. Fradley, Joseph Carver, Jesse Chittams, Marielle Scherrer-Crosbie   +10 more
doaj   +1 more source

Potent immune-dependent anticancer effects of the non-cardiotoxic anthracycline aclarubicin

OncoImmunology
Aclarubicin (also called aclacinomycin A) is an antineoplastic from the anthracycline class that is used in China and Japan but not in Europe nor in the USA.
Giulia Cerrato, Allan Sauvat, Mahmoud Abdellatif, Guido Kroemer   +3 more
doaj   +1 more source

Extrato hidroalcoolico da casca do pequi (Caryocar brasiliense) em ratos submetidos à aplicação de doxorrubicina Hydro alcoholic extract of pequi peel (Caryocar brasiliense) in rats submitted to the application of doxorubicin

Ciência Rural, 2013
O objetivo deste estudo foi avaliar o efeito antioxidante do extrato hidroalcoolico da casca do pequi (EHCP) em ratos após a administração de doxorrubicina (DOX).
Léa Resende Moura, Aparecida Conceição Martins, Liliam Aparecida da Rocha Vaz, Stiwens Roberto Trevisan Orpinelli, Thiago Lopes da Silva, Mariana Batista Rodrigues Faleiro, Suzana da Costa Santos, Veridiana Maria Briagnezi Dignani de Moura   +7 more
doaj   +1 more source